nach oben

Erschienen in:

01.12.2001 | Adis New Drug Profile

Oral Tegafur/Uracil

Erschienen in: Drugs & Aging | Ausgabe 12/2001

Einloggen, um Zugang zu erhalten

Abstract

▲ Tegafur is a prodrug of the antineoplastic agent fluorouracil, and is administered in a 1:4 molar ratio with the fluorouracil modulator uracil.

▲ Oral tegafur/uracil 300 mg/m²/day plus calcium folinate 75 or 90 mg/day for 28 days every 35 days was as effective as intravenous (IV) fluorouracil 425 mg/m²/day plus folinic acid 20 mg/m²/day for 5 days every 28 or 35 days in the treatment of patients with metastatic colorectal cancer in two large, randomised, nonblind, multicentre trials (n = 816 and 380).

▲ Median survival time among patients treated with tegafur/uracil or fluorouracil was approximately 12 months in both trials. Results from both trials also demonstrated no significant between-group differences in overall response rates among patients treated with oral tegafur/uracil (12 and 11%) or IV fluorouracil (15 and 9%).

▲ In elderly patients (aged ≥70 years) with metastatic colorectal cancer, results from small noncomparative studies showed that treatment with oral tegafur/uracil afforded overall response rates of 12.5 to 29% and was well tolerated.

▲ During preoperative treatment with oral tegafur/uracil plus calcium folinate as an adjunct to radiotherapy in patients with stage II or III rectal cancer, the maximum tolerated dosage of tegafur/uracil was 350 mg/m²/day (administered 5 days per week for 5 weeks). Among the 15 patients who were followed for 5 to 8 months, three had a complete response to treatment. Treatment with tegafur/uracil was also given postoperatively

▲ The most common adverse events associated with oral tegafur/uracil were anaemia, nausea/vomiting, diarrhoea, thrombocytopenia, mucositis, neutropenia, asthenia, anorexia and abdominal pain.

▲ Oral tegafur/uracil was associated with a significantly more favourable tolerability profile than IV fluorouracil in the two large randomised trials. In particular, stomatitis and most adverse haematological events were less frequent.

Boyle P, Langman JS. ABC of colorectal cancer: epidemiology. BMJ 2000; 321:805–8PubMedCrossRef

Huang EH, Whelan RL. Tumours of the colon and rectum. Rakel RE. Conn’s Current Therapy. 2000 ed. Philidelphia: W.B. Saunders Company, 2000: 532–7

Hoff PM, Lassere Y, Pazdur R.Tegafur/uracil + Calcium folinate in colorectal cancer: double modulation of fluorouracil. Drugs 1999; 58 Suppl.: 77–83PubMedCrossRef

Pazdur R, Hoff PM, Medgyesy D, et al. The oral fluorouracil prodrugs. Oncology (Huntington) 1998; 12(10): 48–51

Murad AM, de Andrade CA, Delfino C, et al. Pharmacoecono-mic evaluation of tegafur-uracil (UFT) vs fluorouracil for the management of colorectal cancer in Brazil and Argentina. Clin Drug Invest 1997; 13: 90–8CrossRef

Murad A, de Andrade CA, Delfino C, et al. A pharmacoecono-mic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America. Oncology (Huntington) 1997; 11: 128–35

Meropol NJ. Oral fluoropyrimidines in the treatment of colorectal cancer. Eur J Cancer 1998; 34: 1509–13PubMedCrossRef

Bristol-Myers Squibb Pharmaceuticals Ltd. Uftoral capsules [online]. Available from URL: http://emc.vhn.net/eMC/as-sets/c/html/DisplayDoc.asp?DocumentId=4399 [Accessed 2001 Nov 27]

Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215–37PubMedCrossRef

10.

Thomas DM, Zalcberg JR. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol 1998; 25: 887–95PubMedCrossRef

11.

Maehara Y, Kakeji Y, Ohno S, et al. Scientific basis for the combination of tegafur with uracil. Oncology (Huntington) 1997 Sep; 11 (Suppl. 10): 14–21

12.

Hoff PM, Pazdur R. UFT plus oral leucovorin: anew oral treatment for colorectal cancer. Oncologist 1998; 3: 155–64PubMed

13.

Ikenaka K, Shirasaka T, Kitano S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 1979; 70: 353–9PubMed

14.

Fujii S, Kitano S, Ikenaka K. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979; 70: 209–14PubMed

15.

Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Huntington) 1999; 13:17–21

16.

Fujii S, Kitano S, Ikenaka K, et al. Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives. Gan To Kagaku Ryoho 1979; 6: 377–84

17.

Fukui T, Imabayashi N, Nishi M, et al. Clinical study on the enhancement of drug delivery into tumor tissue by using UFT. Gan To Kagaku Ryoho 1980; 7: 2124–9

18.

Sakamoto S, Kudo H, Kuwa K, et al. Effects of neo-adjuvant chemotherapy with UFT (a combination of tegafur and uracil) on DNA-synthesizing enzyme activities in human colorectal carcinomas [in Japanese]. Nippon Gan Chiryo Gakkai Shi 1989; 24: 94–8PubMed

19.

Kanimoto Y, Suzuki Y, Miwa Y, et al. Thymidylate synthase inhibition and concentration of 5-fluorouracil after administration of UFT in human uroepithelial carcinomas [in Japanese]. Hinyokika Kiyo 1991; 37: 229–33PubMed

20.

Suzuki M, Sekiguchi I, Tamada T, et al. Level of inhibition of thymidylate synthase activity and 5-fluorouracil in tumor tissues after administration of UFT or tegafur [in Japanese]. Nippon Gan Chiryo Gakkai Shi 1989; 24: 1399–404PubMed

21.

Tsujimoto T, Sakai S, Murata M, et al. Concentrations of 5-FU in the tissue and serum of the patients with head and neck malignant tumors by preoperative administration of UFT. Gan To Kagaku Ryoho 1983; 10: 78–83

22.

Suemasu K, Nomoto C, Higashi Y. Concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT. Gan To Kagaku Ryoho 1982; 9: 667–71PubMed

23.

Yamashita K, Mitani K, Morishita Y, et al. The concentration of 5-fluorouracil in blood and tissues of the patients with carcinoma of the cervix after administration of UFT and 5-fluorouracil [in Japanese]. Gan To Kagaku Ryoho 1989; 16: 767–73PubMed

24.

Inaba S, Kondo Y, Tsuchiya K, et al. Concentration of 5-fluo-rouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT [in Japanese]. Gan To Kagaku Ryoho 1992; 19: 2175–80PubMed

25.

Hoff PM, Pazdur R, Benner SE, et al. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 1998; 9: 479–90PubMed

26.

Pazdur R. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin. Oncology (Huntington) 1997; 11 (Suppl. 10): 35–9

27.

Ho DH, Covington W, Brown N, et al. Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. Cancer Chemother Pharmacol 2000; 46: 351–6PubMedCrossRef

28.

Pazdur R, Patt Y, Ajani J, et al. Phase II/pharmacology study of UFT (BMS-200604) and leucovorin in refractory colorectal cancer patients [abstract no. 959]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17–20; Denver (CA), 16

29.

Ho DH, Pazdur R, Covington W, et al. Comparison of 5-fluo-rouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus Ni-(2’-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 1998; 4: 2085–8PubMed

30.

Meropol NJ, Sonnichsen DS, Birkhofer MJ, et al. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Cancer Chemother Pharmacol 1999; 43: 221–6PubMedCrossRef

31.

Damle B, Kaul S, Sonnichsen D, et al. Effect of food on the oral bioavailability of UFT and leucovorin in patients [abstract no. 3138]. 91st Annual Meeting of the American Association of Cancer Research; 2000 Apr 1–5; San Francisco (CA), 41

32.

Muggia FM, Wu X, Spicer D, et al. Phase I and pharmacokinetic study of oral UFT, a combination of the 5- fluororuacil prodrug tegafur and uracil. Clin Cancer Res 1996; 2: 1461–7PubMed

33.

Pazdur R, Douillard J-Y, Skillings JR, et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer [abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 18

34.

Carmichael J, Popiela D, Radstone S, et al. Randomized comparative study of ORZEL® (oral uracil/tegafur (UFT™) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer [abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 18

35.

Pazdur R, Lassere Y, Rhodes V, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12: 2296–300PubMed

36.

Aranda E, Anton-Torres A, Sastre J, et al. UFT plus leucovorin (LV) in advanced colorectal cancer (CCR). A phase II trial [abstract no. 153]. Eur J Cancer 1999 Apr; 35

37.

Lin J-K, Wang W-S, Hsieh R-K, et al. Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience. Jpn J Clin Oncol 2000; 30:510–4PubMedCrossRef

38.

Thomas MB, Langleben A, Rinaldi D, et al. Aphase II study of UFT + leucovorin given as a twice daily (bid) regimen in the treatment of patients (pts) with metastatic colorectal cancer (MCC) [abstract no. 564]. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12–15; San Francisco (CA), 20 (Part 1)

39.

Saltz LB, Leichman CG, Young CW, et al. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin: an active oral regimen for advanced colorectal cancer. Cancer 1995; 75: 782–5PubMedCrossRef

40.

Gonzalez-Barón M, Feliu J, de la Gándara I, et al. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 1995; 31A(13/14): 2215–9PubMedCrossRef

41.

Sanchiz F, Milla A. Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer. Jpn J Clin Oncol 1994; 24: 322–6PubMed

42.

Thongprasert S, Maoleekoonpairoj S, Laohavinij S, et al. Efficacy of UFT plus oral leucovorin in advanced colorectal cancer: a multicenter study. J Med Assoc Thai 2000; 83: 676–80PubMed

43.

Meropol NJ, Rustum YM, Petrelli NJ, et al. Aphase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 1996; 37: 581–6PubMedCrossRef

44.

Pazdur R, Lassere Y, Diaz-Canton E, et al. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28 day schedule. Cancer Invest 1998; 16(3): 145–51PubMedCrossRef

45.

Pazdur R, Lassere Y, Diaz-Canton E, et al. Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities. Anticancer Drugs 1996; 7: 728–33PubMedCrossRef

46.

Malik ST, Talbot D, Clarke PI, et al. Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 1990; 62: 1023–5PubMedCrossRef

47.

Gonzalez-Barón M, Feliu J, Ordonez A, et al. Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal. Anticancer Res 1993; 13: 759–62PubMed

48.

Pazdur R, Lassere Y, Diaz-Canton E, et al. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule. Invest New Drugs 1997; 15: 123–8PubMedCrossRef

49.

Marti JL, Escudero P, Alonso V, et al. Phase I-II trial of weekly irinotecan (CPT-11) combined with UFT as second-line treatment in advanced colorectal carcinoma (ACRC) [abstract no. GI3-04]. 11th International Congress on Anti-Cancer Treatment; 2001 Feb 6; Paris

50.

Gravalos C, Garcia-Alfonso P, Castellanos D, et al. Phase I trial of escalating doses of irinotecan in combination with UFT/folinic acid in patients with advanced colorectal cancer[abstract]. Ann Oncol 2000; 11 (Suppl. 4): 199P

51.

Hill M, MacKay H, Cunningham D, et al. Phase I/II study of oral uracil/tegafur (UFT®), leucovorin and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2000; 11 (Suppl. 4): abstract no. 193P

52.

Garcia-Giron C, Feliu J, Vincent JM, et al. Phase II trial of oxaliplatin-UFT-leucovorin (OXA-UFT-LV) combination in first line treatment of advanced colorectal cancer (ACC) [abstract no. 1148]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20–23; New Orleans (LA), 19

53.

Dorta FJ, Feliu J, Vicent J, et al. Phase II clinical trial with the combination of oxaliplatin-UFT-1,-leucovorin (OXA-UFTI, LV) for the first line treatment of advanced colorectal cancer (AAC). Preliminary results (Oncopaz Cooperative Group — Spain) [abstract]. Ann Oncol 2000; 11 (Suppl. 4): 220P

54.

Estevez SV, Vieitez JM, Garcia AP, et al. Raltitrexed combined with UFT: a phase I/II dose escalation study in metastatic colorectal cancer [abstract]. Ann Oncol 2000; 11 (Suppl. 4): 229P

55.

Ikeda E, Kodaira S, Teramoto T, et al. Optimal dosage of UFT+ MMC combination chemotherapy for advanced colorectal cancer-phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration-Study Group of UFTM Therapy for Advanced Colorectal Cancer [in Japanese]. Gan To Kagaku Ryoho 1996; 23: 1291–8PubMed

56.

González-Barón M, Feliu J, de la Gándara I, et al. Phase II trial of uracil-tegafur (UFT), leucovorin (LV) and mitomycin-C in advanced colorectal cancer. Ann Oncol 1994; 5 (Suppl. 8): abstract no. 263

57.

Asano M, Mori T, Takahashi K, et al. Low dose cisplatin added to continuous infusion of 5-fluorouracil or oral administration of UFT for inoperable advanced or recurrent colorectal cancer [in Japanese]. Gan To Kagaku Ryoho 1997; 24(1): 55–60PubMed

58.

Sadahiro S, Ohki S, Yamaguchi S, et al. Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer. Cancer Chemother Pharmacol 2000; 46: 180–4PubMedCrossRef

59.

Yanagi H, Kusunoki M, Yoshikawa R, et al. Clinical results of pharmacokinetic modulating chemotherapy (PMC) in combination with hepatic arterial 5-FU infusion and oral UFT after resection of hepatic colorectal metastases [abstract no. 556]. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12–15; San Francisco (CA), 20 (Parti)

60.

Fujii M, Kochi M, Sawa H, et al. Preoperative and postoperative adjuvant chemotherapy for colorectal cancer — Results of 5-year survival using UFT: a pilot study [in Japanese]. J Jpn S oc Cancer Ther 1995; 30(3): 584–94

61.

Nakazato H, Koike A, Sail S, et al. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: a prospective randomized clinical trial [abstract no. 990]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17–20; Denver (CA), 16.

62.

Mok TSK, Leung TWT, Chan ATC, et al. A phase III randomized study of oral UFT (tegafur + uracil) as maintenance therapy in adjuvant treatment of surgically resected colorectal cancer patients [abstract no. 1042]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 16–19; Los Angeles (CA), 17

63.

Kodaira S, Kikuchi K, Yasutomi M, et al. Postoperative adjuvant chemotherapy with mitomycin C and UFT for curatively resected rectal cancer. Results from the Cooperative Project No. 7 Group of the Japanese Foundation for Multidisciplinary Treatment of Cancer. Int J Clin Oncol 1998; 3: 357–64CrossRef

64.

Nakagoe T, Ishikawa H, Sawai T, et al. Multicenter randomized prospective study of adjuvant chemotherapy with UFT and mitomycin C in advanced colorectal cancer. Anticancer Res 2000; 20: 1069–75PubMed

65.

Mitomi T, Tsuchiya S, Hiki Y, et al. A randomized controlled study on adjuvant chemotherapy with UFT in curatively resected colorectal cancer [abstract no. 690]. Proceedings of the 29th Annual Meeting of the American Society of Clinical Oncology; 1993 May 16–18; Orlando (FL), 12

66.

Hoff PM, Janjan N, Saad ED, et al. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol 2000; 18: 3529–34PubMed

67.

Pfeiffer P. Concurrent UFT/L-leucovorin and curative intended radiotherapy (60 GY) in patients with locally advanced rectal cancer: a phase I/II trial [abstract no. 992]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20–23; New Orleans (LA), 19

68.

Bristol-Myers Squibb Company — Oncology Division Europe. UFT® — tegafur-uracil capsules: product overview [media release]. 2001

69.

Díáz-Rubio E, Sastre J, Abad A, et al. UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. Oncology (Huntington) 1999; 13 (Suppl. 3): 35–40

70.

Feliu J, Gonzalez-Barón M, Espinosa E, et al. Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer 1997; 79: 1884–9PubMedCrossRef

71.

Ferrari VD, Barni S, Mandalà M, et al. Tegafur (T) plus folinic acid (FA) as first line treatment of advanced colorectal cancer (ACC) in patients (pts) aged over 70 years. GISCAD (Ialian [sic] Group for the Study of Digestive Tract Cancer). Ann Oncol 2000; 11 (Suppl. 4): abstract no. 235P

72.

Skillings JR. 5-FU or UFT combined with leucovorin for previously untreated metastatic colorectal Ca. Oncology (Huntingt) 1997; 11 (Suppl. 10): 48–9

73.

Carmichael J. UFT plus leucovorin vs 5-FU plus leucovorin for metastatic colorectal cancer. Oncology (Huntington) 1997; 11 (Suppl. 10): 50–2

74.

Royce ME, Hoff PM, Pazdur R. Progress in colorectal cancer chemotherapy: how far have we come, how far to go? Drugs Aging 2000; 17: 201–16PubMedCrossRef

75.

Data on file. Bristol-Myers Squibb Germany. 2002

76.

Borner M, Schsffski P, de Wit R, et al. A randomized crossover trial comparing oral UFT (uracil/tegafur) + leucovorin (LV) and intravenous fluorouracil (FU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer [abstract no. 741]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20–23; New Orleans (LA), 19

Titel: Oral Tegafur/Uracil
Publikationsdatum: 01.12.2001
Erschienen in: Drugs & Aging / Ausgabe 12/2001
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200118120-00005

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2001

Tegafur/Uracil

Cytomegalovirus and the Aging Population

Strategies for Management of Prostate Cancer-Related Bone Pain